Conversion Therapy for Stage IV Gastric Cancer: Report From the Expert Consensus Meeting at KINGCA WEEK 2024
- Author:
Tae-Han KIM
1
;
Ichiro UYAMA
;
Sun Young RHA
;
Maria BENCIVENGA
;
Jiyeong AN
;
Lucjan WYRWICZ
;
Dong-Hoe KOO
;
Richard van HILLEGERSBERG
;
Keun-Wook LEE
;
Guoxin LI
;
Takaki YOSHIKAWA
;
Brian BADGWELL
;
Sylvie LORENZEN
;
In-Ho KIM
;
In-Seob LEE
;
Hye-Sook HAN
;
Hur HOON
Author Information
- Publication Type:Special Article
- From:Journal of Gastric Cancer 2025;25(1):133-152
- CountryRepublic of Korea
- Language:English
- Abstract: Conversion therapy is a treatment strategy that shifts from palliative systemic therapy to curative surgical treatment for primary and/or metastatic stage IV gastric cancer (GC).To address its clinical statements, the Korean Gastric Cancer Association aims to present a consensus on conversion therapy among experts attending KINGCA WEEK 2024. The KINGCA Scientific Committee and Development Working Group for Korean Practice Guidelines prepared preformulated topics and 9 clinical statements for conversion therapy.The Delphi method was applied to a panel of 17 experts for consensus and opinions. The final comments were announced after the statement presentation and discussed during the consensus meeting session of KINGCA WEEK 2024. Most experts agreed that conversion herapy provides a survival benefit for selected patients who respond to systemic therapy and undergo R0 resection (88.3%). Patients with limited metastases were considered good candidates (94.2%). The optimal timing was based on the response to systemic therapy (70.6%). The regimen was recommended to be individualized (100%) and the duration to be at least 6 months (88.3%). A minimally invasive approach (82.3%) and D2 lymph node dissection (82.4%) were considered for surgery. However, resection for metastases with a complete clinical response after systemic therapy was not advocated (41.2%). All experts agreed on the need for large-scale randomized-controlled trials for further evidence (100%).Recent advancements in treatment may facilitate radical surgery for patients with stage IV GC. Further evidence is warranted to establish the safety and efficacy of conversion therapy.
